Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 772 of 6351
-
New TB vaccine trial aims to stop infection before it starts
Vaccine OngoingTuberculosis (TB) is an infection caused by bacteria passed from one person to another through the air when an infected person for instance coughs, speaks, or sneezes. This study tests the safety and vaccine-induced immune response of a new preventive TB vaccine called H107e/CAF®…
Phase 1 • Sponsor: Statens Serum Institut • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
New epilepsy drug shows promise in reducing seizures
Disease control Recruiting nowThe purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New obesity drug cocktail aims to melt fat, not muscle
Disease control OngoingThis study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug DZD8586 enters phase 2 trial
Disease control CompletedThis study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also…
Phase 2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Three-Drug cocktail calm a suicidal crisis in days?
Disease control CancelledThis is an inpatient four-arm randomized control trial comparing single drug clonazepam (S arm), a two-drug combination clonazepam/olanzapine (D arm), and a three-drug combination clonazepam/olanzapine/buprenorphine (T arm) with treatment as usual (TAU arm) in the treatment of em…
Phase 4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug hope for kids with Crohn's: mirikizumab enters final testing
Disease control Recruiting nowStudy participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric part…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug could reverse liver scarring in MASH patients
Disease control Recruiting nowThe study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
Phase 3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a herbal oil shield cancer patients from chemo nerve pain?
Prevention Recruiting nowThe clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological …
Phase 3 • Sponsor: WALA Heilmittel GmbH • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
New hope for kids with Crohn's: drug trial targets gut healing
Disease control Recruiting nowThe purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a smartphone app tame Alcohol-Related liver disease?
Disease control CompletedThe purpose of this study is to determine whether a multidisciplinary digital clinic will improve health outcomes, reduce costs, increase access, and improve provider satisfaction. The primary aim of this study is to improve clinical outcomes in patients with ALD through the imp…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Radiation-Free breast cancer treatment? new trial tests skipping it after chemo success
Disease control Recruiting nowTo de-escalate radiation therapy in women with breast cancer.
Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cheaper keytruda? new biosimilar SB27 tested in lung cancer
Disease control OngoingThe goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is: • How effective the study drug is Participants will receive either investigat…
Phase 3 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumo…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New liquid biopsy could spot hidden brain lymphoma
Diagnosis OngoingPrevention and treatment of CNS relapse remains a great unmet clinical need in the management of aggressive B-NHL. Hence, investigating novel diagnostic tests is of paramount importance to improve risk-stratification of lymphoma patients at diagnosis, as is the evaluation of nove…
Sponsor: Swiss Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Experimental CAR T-Cell therapy takes on metastatic prostate cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New Gene-Modified immune cells take on tough lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational…
Phase 1/2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Leukemia patients who failed stopping meds may get another shot at drug-free remission
Disease control Recruiting nowTo evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Phase 2 • Sponsor: Korean Society of Hematology • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to tackle tough esophageal cancer
Disease control Recruiting nowThe goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitor…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New immunotherapy combo aims to stop merkel cell cancer return
Disease control Recruiting nowThe goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyTo evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC